Translational Lung Research Center Heidelberg

News

September 2017: The newspaper ZEIT presents: DZL - a 5-year success story

In a special edition "World of Science: Cutting-Edge Research" the newspaper ZEIT reports on the five-year success story of the German Center for Lung Research (DZL). Five research highlights provide insight into the current advancement in research for a wide range of lung diseases. The interdisciplinary approach to lung research for the benefit of patients is at the core of this research network, involving 28 leading German research insitutions and university hospitals. Professor Werner Seeger, chair of the DZL, is interviewed about the importance of lung research, the international visibility and his vision for the future of the DZL. Besides the print edition there is access to additional research highlights in the ZEIT ONLINE edition.

 

Link to ZEIT ONLINE (in German):

http://www.dzl.de/index.php/de/presse-und-events/news/363-zeit-praesentiert-5-jahre-erfolgsgeschichte-des-dzl

 


01.08.2017: From August 1st, Professor Dr. Hauke Winter will take up his new position as chief physician and head of the Department of Thoracic Surgery at the Thoraxklinik Heidelberg.

 

 

 

Read More ... (Press Release in German)

 


July 2017: German Council of Science and Humanities endorses the German Centers for Health Research as a promising modell for medical research

 

The modell German Centers for Health Research (Deutsche Zentrum für Gesundheitsforschung (DZG)) is well suited to closely connect all relevant national players on an institutional level as well as in terms of infrastructure and long-term perspective, to manage the translational process. This is the verdict of the German Council of Science and Humanities based on a recently published evaluation of this particular funding scheme. "The establishment of German Centers for Health Research provides valuable added value to the German resarch landscape" underlines the chairman of the Council of Science and Humanities, Professor Martina Brockmeier.

Read more ... (Press Release in German)


 

 

June 2017: How does pathological iron overload affect the lung?

Figure: Microscopic image of mouse lung tissue with iron overload. Cells that accumulate iron, as marked by the arrows, turn a deep brown colour.

Scientists from the German Center for Lung Research (DZL) developed an animal model of severe iron overload to investigate the mechanisms of pulmonary iron deposition and their effects on lung function. In this animal model the iron overload resulted in elevated lung rigidity and reduced lung capacity. This is of particular interest not only for patients with iron overload due to genetic disorders but also for patients with other chronic restrictive lung diseases that are frequently associated with alterations in pulmonary iron homeostasis. The finding that iron deposition in the lung may cause or increase the severity of lung disease rather than be a byproduct of lung disease will be further investigated.


This interdisciplinary project led by Professor Muckenthaler from the Department of Oncology, Hematology, Immunology and Pulmonology of the Heidelberg Children’s Hospital also involved the Department of Translational Pulmonology at Heidelberg University Hospital and scientists from the DZL sites Institute of Functional and Applied Anatomy, Biomedical Research in Endstage and Obstructive Lung Disease Hannover and Universities of Giessen and Marburg Lung Center.

Press Release (in German)

 

Literature:
Neves J, Leitz D, Kraut S, Brandenberger C, Agrawal R, Weissmann N, Mühlfeld C, Mall MA, Altamura S, Muckenthaler MU. Disruption of the Hepcidin/Ferroportin Regulatory System Causes Pulmonary Iron Overload and Restrictive Lung Disease. EBioMedicine. 2017 Apr 29. pii: S2352-3964(17)30191-3. doi: 10.1016/j.ebiom.2017.04.036. [Epub ahead of print]


 

May 2017: The Eurpoean Respiratory Society (ERS) elects Professor Marcus Mall as Fellow of ERS (FERS)

 

The Fellow of ERS award recognises excellence in contributions to research, education and clinical leadership in respiratory medicine from amongst the ERS membership.
The award brings together members who have excelled in their field to form an elite advisory board that will be called upon by the society on various matters in future years.

 

The 2017 reception for new Fellows of ERS will take place during the ERS Congress in Milan, in September.

 

 

 


 

 

May 2017: The DZL celebrates its 5th Anniversary in the Heidelberg Old Town

 

On the occasion of its 5th anniversary, the public was invited to visit the DZL stall right in the middle of Heidelberg's historic city center. Information leaflets about reseach successes, a lung quiz and a mobile unit offering lung function tests free of charge attracted young and old passers-by.

 

Read more ... (in German)

 

 

 


 

 

February 2017: 15th Symposium of the Cystic Fibrosis Center Heidelberg

The 15th Symposium of the Cystic Fibrosis Center Heidelberg focused on new therapies for the treatment of the CF basic defect and the treatment of diabetes in CF patients. Over 180 patients, next of kin and care professionals attended the symposium.

 

Initiates file downloadRead more ... (Press Release in German)

Opens external link in new windowVideo Clips der Vorträge (in German)

 

 

 

 


December 2016: Targeting impaired mucus clearance to fight asthma triggers

Illustration of disease mechanism

Scientists from the Translational Lung Research Center Heidelberg (TLRC) identify an important disease mechanisms of allergic asthma and potential new therapeutic strategies.

 

Results recently published in the Journal of Allergy and Clinical Immunology showed that in juvenile mice impaired mucus clearance causing reduced clearance of inhaled allergens is an important risk factor for allergen-induced type-2 airway inflammation. Further, it was demonstrated that the airway epithelium itself is a key player in triggering the immune response. If allergens were not removed efficiently because of impaired mucus clearance the airway epithelium released the messenger molecule Interleukin-13 (IL-13), which activates specific cells of the immune system (T-helper cells type 2 (Th2)), thus triggering inflammation. "This is a new finding: the allergic inflammation in the lung is not primarily triggered by dysfunctional immune cells. Instead the immune cells respond to a call for help by the airway epithelium. Though allergens themselves also trigger an immune response, this is less pronounced when there is no concurrent impairment of mucus clearance", explains Professor Mall.  On treating the juvenile mice with the drug amilorid, which improved the mucus clearance, less IL-13 was released and the allergic reaction less pronounced. These results suggest therapeutic improvement of airway mucus clearance as a novel treatment strategy for patients with allergen-induced asthma.


This research was conducted in close collaboration with colleagues from the unit of Pediatric Pulmonology and Allergology at the Center for Pediatric and Adolescent Medicine at the University Hospital Heidelberg and was funded by the German Center for Lung Research (DZL).

 

 

Further Information:

Opens external link in new windowPress Release in German

External Link to Publication: Opens external link in new windowFritzsching B, Hagner M, Dai L, Christochowitz S, Agrawal R, van Bodegom C, Schmidt S, Schatterny J, Hirtz S, Brown R, Goritzka M, Duerr J, Zhou-Suckow Z, Mall MA. Impaired mucus clearance exacerbates allergen-induced type 2 airway inflammation in juvenile mice.J Allergy Clin Immunol. doi: 10.1016/j.jaci.2016.09.045 [Epub ahead of print]

 


November 2016: Non-invasive and radiation-free early diagnosis and therapeutic monitoring of patients with cystic fibrosis lung disease

Patient with CF performing a lung volume ventilation measurement
(Photo: Heidelberg University Hospital)

Results recently published in the American Journal of Respiratory and Critical Care Medicine confirm the sensitivity of magnetic resonance imaging (MRI) and the lung clearance index (LCI),  a measure of abnormal ventilation distribution, to detect damage to the lung from early infancy. This is the first study to systematically compare both methods from infancy to early adulthood in patients with cystic fibrosis. “The study results are not only a breakthrough for diagnosis and disease monitoring but these methods allow us to test new preventive therapeutic strategies that we developed over the past few years with minimalizing the burden for our young patients” says Professor Dr. Marcus Mall, Medical Director of the Department of Translational Pulmonology at the Translational Lung Research Center Heidelberg (TLRC), Head of Pediatric Pulmonology and the Cystic Fibrosis Center.

 


The study was conducted in at the Translational Lung Research Center Heidelberg (TLRC) in close collaboration with the Cystic Fibrosis Center at the Center for Pediatric and Adolescent Medicine, the Department for Diagnostic and Interventional Radiology, and the Department of Translational Pulmonology at Heidelberg University Hospital. The research was funded by the German Center for Lung Research (DZL), the Dietmar Hopp Foundation and the German Cystic Fibrosis Foundation (Mukoviszidose e.V.).


Further Information:
Opens external link in new windowPress Release in German

External Link to Publication: Opens external link in new windowMirjam Stahl, Mark O Wielpütz, Simon Y Graeber, Cornelia Joachim, Olaf Sommerburg, Hans-Ulrich Kauczor, Michael Puderbach, Monika Eichinger, Marcus A Mall.Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children With Cystic Fibrosi. Am J Respir Crit Care Med 20165 Aug 30 (Epub ahead of print)


 

 

November 2016: DZL meets German Cystic Fibrosis Foundation (Mukoviszidose e.V.)

The 19th German Cystic Fibrosis Conference took place from November 17th to 19th 2016, in Würzburg. More than 800 participants from various professions involved in the treatment and care of patients with cystic fibrosis discussed the most up-to-date research findings, new therapeutic concepts and other aspects of disease management. An important focus of the conference was the cystic fibrosis research program of the German Center for Lung Research (DZL).

 

Further information:

DZL Press Release in German

Mukoviszidose e.V. Press Release in German

 

 

 

 

Tagungsleiter Prof. Dr. Marcus Mall (li)

und Prof. Dr. Burkhard Tümmler (re)

 

 


 

 

September 2016: Tracking lung cancer therapy and response in blood samples: successful proof-of-concept study

 

Scientists at the German Center for Lung Research (DZL), located at the German Center for Cancer Research (DKFZ), the National Center for Tumor Diseases and the Thoraxklinik in Heidelberg used liquid biopsies to detect mutations in circulating cell free DNA (cfDNA) in non-small-cell lung cancer (NSCLC) patients, which may provide a promising tool for early indication of therapy response and tumor progression in lung cancer patients. In this joint project serial liquid biopsies from sixteen NSCLC patients treated with tyrosin kinase inhibitor (TKI) were investigated. The results show that the liquid biopsy approach is sufficiently sensitive to detect changes in the tumor in real time. With early and frequent sampling this method promises to identify mutations in cfDNA prior to clinically detectable disease progression.
Opens external link in new windowRead more … (Press release in German)

Literature:

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.

Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M, Sültmann H. Sci Rep. 2016 Sep 19;6:33505. doi: 10.1038/srep33505.

 


 

 

September 2016: TLRC clinicians teach postgraduate courses at the European Respiratory Society (ERS) International Congress 2016, in London

 

The ERS is the largest meeting in the world in the respiratory field. The scientific program presents the best in science and educational sessions from distinguished researchers from across the globe. We are very pleased that TLRC Scientists PD Dr. med. Mark O. Wielpütz, Professor Dr. med. Ralf Eberhardt and Dr. med. Daniela Gompelmann were chosen to teach up-to-date knowledge within the following Postgraduate Course Sessions:

 

PG5 - How to reach peripheral nodules

PG14 - Interventional Pulmonology

  • Interventions for obstruction: endoscopic lung volume reduction/thermoplasty (Opens internal link in current windowD. Gompelmann)

 

 

May 2016: „BAMBI“– a potential new therapeutic target for non-small-cell lung cancer

Characteristic for non-small-cell lung cancer (NSCLC) is early metastatic disease and high mortality. Researchers at the German Center for Lung Research (DZL), located at the Airway Research Center North (ARCN) and the Translational Lung Research Center Heidelberg (TLRC), have identified a potential new therapeutic target for NSCLC. It is based on the differential regulation of the TGF-β signaling pathway by its pseudo-receptor BAMBI. The study is published today in the online issue of Cancer Research. Read more ...

 

Literature: Marwitz S, Depner S, Dvornikov D, Merkle R, Szczygiel M, Müller-Decker K, Lucarelli P, Wäsch M, Mairbäurl H, Rabe KF, Kugler C, Vollmer E, Reck M, Scheufele S, Kröger M, Ammerpohl O, Siebert R, Goldmann T, Klingmüller U (2016) Downregulation of the TGF-β pseudoreceptor BAMBI in non-small cell lung cancer enhances TGF-β signaling and invasion. Cancer Research 2016 May 17 [Epub ahead of print]

External link to the article:
cancerres.aacrjournals.org/content/early/2016/05/17/0008-5472.CAN-15-1326


 

 

April 2016: Professor Ursula Klingmüller, a systems biologist at the German Cancer Research Center (DKFZ) and principal investigator at the Translational Lung Research Center Heidelberg (TLRC), member of the German Center for Lung Research (DZL), has been appointed to the German Ethics Council.

Further information:

Opens external link in new windowDKFZ Press Release in German

Opens external link in new windowGerman Ethics Council

 

Foto: DKFZ

 


Prof. Michael Kreuter

March 2016: The issue of antacid therapy in patients with IPF

The incidence of gastro-oesophageal reflux is higher in patients with IPF compared to the general population. Since the 2011 international guidelines there exists a conditional recommendation for the use of antacid therapy, i.e. PPI or H2-blockers, in patients with IPF. This was based on data which suggested that IPF patients taking AAT have less deterioration of pulmonary function parameters potentially due to decreasing micro-aspiration associated lung injury and damage. However, the low confidence in estimates of the effect prompted DZL-scientist Prof. Michael Kreuter to initiate a new post-hoc analysis pooling data from the placebo arms of three multinational trials on pirfenidone in IPF. In this new analysis, published in Lancet Respiratory Medicine1, antacid therapy was not associated with a slower disease progression in IPF. Moreover, in patients with advanced disease antacid therapy was associated with a significantly higher incidence of pulmonary and non-pulmonary infections. These findings do not support the conditional recommendation for antacid therapy and underline the urgent need for long-term, randomised, placebo-controlled studies to investigate the effect of antacid therapy in patients with IPF, particularly in those with advanced disease.

 

Literature:
Opens external link in new window1Michael Kreuter, Wim Wuyts, Elisabetta Renzoni, Dirk Koschel, Toby M Maher, Martin Kolb, Derek Weycker, Paolo Spagnolo, Klaus-Uwe Kirchgaessler, Felix J F Herth, Ulrich Costabel. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine, Published online: 31 March 2016

Opens external link in new windowSteven D Nathan. Antacid therapy and idiopathic pulmonary fibrosis: cause for heartburn?
Comment in Lancet Respiratory Medicine, Published online: 31 March 2016

 


March 2016: Treating severe emphysema with vapour ablation – new findings

Since the 1990s, lung volume reduction (LVR) has been successful in improving lung function and quality of life in some patients with severe emphysema. A critical review of the literature, in particular procedures used for lung volume reductions, has prompted DZL-Scientists Felix Herth and Daniela Gompelmann and team to initiate the STEP-UP Trial, which adopted a segmental approach, which targets only the more diseased segments for reduction and reduces the volume treated per session. For this first randomized controlled trial to investigate thermal vapour ablation, study patients between 45 and 75 were recruited at ten hospital sites in Europe and three in Australia. Key inclusion criteria were evidence of upper lobe-predominant heterogeneous emphysema, FEV1 between 20 to 45 % predicted, post-rehabilitation 6-min walk test (6MWT) greater than 140 m, and non-smoking for at least 6 months before study enrolment. Results published in Lancet Respiratory Medicine1 confirmed that compared with standard medical management, targeted thermal vapour ablation of more diseased segments and preservation of less diseased segments resulted in clinically meaningful and statistically significant improvements in lung function and quality of life at 6 months, with an acceptable safety profile.

 

Publication

Opens external link in new window1Herth FJ, Valipour A, Shah PL, Eberhardt R, Grah C, Egan J, Ficker JH, Wagner M, Witt C, Liebers U, Hopkins P, Gesierich W, Phillips M, Stanzel F, McNulty WH, Petermann C, Snell G, Gompelmann D.Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med. 2016 Mar;4(3):185-93.


November 2015: Glycodelin - A New Biomarker for Non-Small Cell Lung Cancer

Expression of glycodelin in the primary tumor and the later diagnosed metastasis of a lung cancer patientTLRC scientist found that Glycodelin, a pregnancy protein, is secreted by non-small cell lung cancer (NSCLC) and its concentration measured in the serum of NSCLC-patients correlates with tumor progression. Preliminary investigations suggest that glycodelin suppresses the immune system in the tumor microenvironment. If confirmed in further studies, glycodelin may proof a useful biomarker for early detection and monitoring of response to therapy in NSCLC patients.

 

Further information:

Opens external link in new windowPress Release (in German)

 

Schneider MA, Granzow M, Warth A, Schnabel PA, Thomas M, Herth FJ, Dienemann, H, Muley T, Meister M. Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Aug 1;21(15):3529-40. doi: 10.1158/1078-0432.CCR-14-2464. Epub 2015 Apr 2


Oktober 2015: Tag der offenen Tür in der Thoraxklinik am 28. November

Unter dem Motto "Lunge – Luft – Leben" lädt die Thoraxklinik am Universitätsklinikum Heidelberg ein zu Vorträgen, Informationsständen und Mitmachaktionen für die ganze Familie.

 

Opens external link in new windowWeitere Informationen

Initiates file downloadFlyer mit Programm

 


October 2015: Attracting Young Talent to Lung Research at the Medical Graduation Event Heidelberg 2015

Committed postdocs of the Department of Translational Pulmonology presented the work of the Department and the Translational Lung Research Center Heidelberg (TLRC), member of the German Center for Lung Research (DZL), at the Medical Graduation Event 2015. A session devoted to postdocs and senior staff from various clinics and institutes presenting their research, provided an excellent opportunity for the about 350 medical students to inform themselves about future doctoral projects. Contacts were made and we consider this event a perfectly stimulating tool for attracting motivated young talent to lung research.

 


August 2015: Early diagnosis, early treatment: a federal joint committee decides on a national newborn screening for cystic fibrosis

From spring 2016, each newborn in Germany will be tested for the hereditary disease cystic fibrosis. A decision taken by the joint federal committee, the supreme decision making body of physicians, physiotherapists, hospitals and health insurance companies. A pilot study undertaken at Heidelberg University Hospital, funded by the Dietmar Hopp Foundation and the German Center for Lung Research, demonstrated that diagnosis by blood test is reliable and can be incorporated into the newborn screening program. This way newborns can be treated and cared for from the very start of life. This will greatly support and improve the physical development and lung function of newborns with cystic fibrosis. The successful Heidelberg study made a decisive contribution to this decision by the joint federal committee.

Opens external link in new windowPress Release (in German)

 


July 2015: A New Professorship for Molecular Thoracic Oncology at the Translational Lung Research Center Heidelberg

Professor Dr. Rocio Sotillo, a molecular biologist previously at EMBL (Monterotondo, Italy), has joined the German Cancer Research Center (DKFZ) to lead the newly formed cooperation unit on the molecular basis of lung tumors. The W3-professorship is a joint appointment between the DKFZ and the Thoraxklinik at Heidelberg University Hospital. The DKFZ and the Thoraxklinik are partners in the Translational Lung Research Center Heidelberg (TLRC), member of the German Center for Lung Research (DZL).  

Read more ...

 


July 2015: Lung damage already common in majority of smokers that do not show any symptoms, yet

A large US trial with smokers shows that despite a normal lung function test, lung damage can already be detected by computer tomography (CT). Based on conventional diagnostic tests it was previously assumed that about 50% of smokers will develop chronic obstructive lung disease (COPD) that results in progressive lung damage. In fact, the CT-based results of the US Respiratory Hospital National Jewish Health Study in 8.800 smokers found that in about 80% of smokers, there are clear signs of lung damage despite nonsymptomatic lung function tests. Prof. Dr. med. Hans-Ulrich Kauczor, Chief of Diagnostic and Interventional Radiologoy at Heidelberg Univesity Hospital, assessed CT images of study participants - "The findings are clear: the majority of smokers suffer from chronic lung damage, even if they have not shown any symptoms, yet. Without treatment the COPD will progress unrelentingly".

Professor Kauczor leads the Platform Imaging of the German Center for Lung Research and spezializes in the advancement of lung imaging. The study has been published in JAMA Internal Medicine.

About 8 million people suffer from COPD in Germany and about 100.000 die each year due to the consequences of progressive lung damage. "COPD in Germany is for the most part avoidable" says the lung expert Professor Dr. Felix Herth, Chief of the Department of Pulmonology and Critical Care Medicine at Thoraxklink at University Hospital Heidelberg. "About 90% of COPD patients still are or were former smokers." Frequently, the lung damage remains hidden, symptoms such as shortness of breath and morning cough are often ignored at first. Once the lung tissue is pathologically altered, it cannot be reversed. The earlier the therapeutic intervention starts the longer the progression of lung disease can be delayed. However, a cure is not possible.

Further Information:

Opens external link in new windowClinical and Radiologic Disease in Smokers With Normal Spirometry: Elizabeth A. Regan, MD et al.; JAMA Intern Med. Published online June 22, 2015. doi:10.1001/jamainternmed.2015.2735

Opens external link in new windowHeidelberg University Hospital Press Release (in German)

 

Opens external link in new windowInterview with Prof. Kauczor (in German)

 


 

 

June 2015: 2015 TLRC Lung Conference / 4th DZL International Symposium

From June 25 -27, leading lung scientists met for the TLRC Lung Conference / 4th DZL International Symposium in Heidelberg to discuss “Frontiers in Chronic and Malignant Airways Disease”. The focus of this conference was on common disease mechanisms that may increase our understanding of pathogenesis, lead to novel therapeutic targets and thus facilitate the development of more effective therapies for chronic and malignant lung diseases. The symposium featured plenary sessions on CF, COPD, lung cancer, mucus and the microbiome by leaders in the respective fields and oral presentations by young scientists selected from the best abstracts submitted. Best of Session Poster Awards were bestowed on Cho-Ming Chao (UGMLC), Milena Costa de Silva (TLRC) and Innokentij Jurastow (UGMLC). 

Initiates file downloadScientific Program

Opens external link in new windowPress Release (in German)


May 2015: Experts recommend screening programs for people at high risk for lung cancer

The two major medical societes ESR (European Society of Radiology) and ERS (European Respiratory Society) recommend the introduction of Europe-wide annual screening programs for people at high risk for lung cancer.

Experts recommend that checkups should be made by means of  low-dose computed tomography. The radiation exposure for patients is significantly lower than in a normal computed tomography of the lungs. The screening programs should also be carried out in clinical trials or in certified medical centers. Cessation programs for smokers are also among the recommendations.


The ESR/ERS White Paper - which was written under the auspices of the Department of Diagnostic and Interventional Radiology Heidelberg (DZL site TLRC) - gives recommendations for policy. “A major study from the US has revealed a significant decrease in lung cancer mortality as a result of a screening programme using computed tomography (CT) of the lung. It is our duty to provide recommendations for the implementation of standardised high-quality screening programmes to help reduce lung cancer deaths in Europe”, said the first author of the paper, Hans-Ulrich Kauczor, from the University Heidelberg and the German Center for Lung Research.

 

Further information:

Kauczor H-U. et al. on behalf of the European Society of Radiology and the European Respiratory Society (2015) ESR/ERS white paper on lung cancer screening.                                                                    
Eur Radiol (epub) DOI 10.1007/s00330-015-3697-0
Eur Resp J (epub) DOI 10.1183/09031936.00033015



Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J; National Lung Screening Trial Research Team. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013 Sep 5; 369(10):920-31 DOI: 10.1056/NEJMoa1208962


February 2015: 3rd Heidelberger Symposium on Rare Lung Diseases

The 3rd Heidelberger Symposium on Rare Lung Diseases, jointly organized by the Thoraxklinik Heidelberg of the DZL TLRC Center and the LungenClinic Großhansdorf of ARCN took place on February 28, 2015 in Heidelberg. Experts in their field of rare lung diseases presented up-to-date knowledge and new insights into diagnostic challenges and therapeutic options for the treatment of rare lung diseases including rare types of asthma, IgG4-related lung disease and CVID-ILD, and Lymphangioleiomyomatosis. For further information please refer to the Initiates file downloadprogram flyer and Initiates file downloadpress release (in German).


February 2015:  Novel target identified for anti-inflammatory therapy in patients with Cystic Fibrosis and potentially other muco-obstructive lung diseases.

TLRC scientists identify an important role of hypoxic epithelial necrosis in the in vivo pathogenesis of neutrophilic inflammation independent of bacterial infection and IL-1R as a novel target for anti-inflammatory therapy in patients with CF and potentially other muco-obstructive lung diseases. For more information please see the Opens external link in new windowpress release (in German) from Heidelberg University Hospital and the publication in the Opens external link in new windowAmerican Journal of Respiratory and Critical Care Medicine.


Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen

News before 2015